Author(s)

Sheng Liu¹, JiaYun Wu^2*

Affiliation(s)

¹Department of General Practice, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.

²Department of Rheumatology and Immunology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.

Corresponding Author

JiaYun Wu

ABSTRACT

Objective To improve the alertness and diagnosis and treatment of systemic lupus erythematosus (SLE) combined with breast cancer through case report and review of related literature. Methods To review the diagnosis and treatment of a patient diagnosed with both systemic lupus erythematosus and breast cancer, summarise the clinical features and follow up the changes in her condition after treatment, and summarise her diagnosis and treatment. Results  The patient was admitted to the hospital with arthralgia accompanied by fever, with a past history of breast hyperplasia, and a complete examination suggesting leukopenia, positive anti-double-stranded DNA antibody and antinuclear antibody, and low complement, which was in line with the classification criteria of systemic lupus erythematosus of the American College of Rheumatology (ACR) of 2019, and the examination of breast ultrasound suggesting a category 4C (the classification of Breast Imaging Reporting and Data System )nodule in the right side of the breast, and puncture pathology suggesting infiltrating carcinoma in the breast, the patient was subsequently treated for both SLE and breast cancer. Conclusion:The onset of SLE is insidious, and after diagnosis of SLE, patients should be aware of the need for regular breast cancer screening, and individualised treatment for both diseases can be carried out.

KEYWORDS

Systemic lupus erythematosus; Breast cancer; Case report

CITE THIS PAPER

Sheng Liu, JiaYun Wu. A case report of simultaneous diagnosis of systemic lupus erythematosus and breast cancer and literature review. Journal of Pharmaceutical and Medical Research. 2024, 6(4): 1-4. DOI: https://doi.org/10.61784/jpmr3017.

REFERENCES

[1] Yildiz O, Gürbüz AF, Karakurt Ery?lmaz M, et al. Drug induced lupus associated with Trastuzumab emtansine in a patient with metastatic breast cancer. J Oncol Pharm Pract, 2024.

[2] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis, 2019, 78(6): 736-745.

[3] Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol, 2021, 39(13): 1485-1505.

[4] Ladouceur A, Clarke AE, Ramsey-Goldman R, et al. Malignancies in systemic lupus erythematosus: an update. Curr Opin Rheumatol, 2019, 31(6): 678-681.

[5] Khaliq W, Qayyum R, Clough J, et al. Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population. Breast Cancer Res Treat, 2015, 151(2): 465-474.

[6] Li W, Wang R, Wang W. Exploring the causality and pathogenesis of systemic lupus erythematosus in breast cancer based on Mendelian randomization and transcriptome data analyses. Front Immunol, 2023, 13:1029884.

[7] Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 2024, 35(2): 159-182.

[8] Md Yusof MY, Smith EMD, Ainsworth S, et al, Vital EM. Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope. Rheumatol Adv Pract, 2023, 7(3): rkad093.

[9] Chen CC, Ho WL, Chen HH, et al. The association between infection incidence and autoimmune diseases in breast cancer patients after anti-cancer treatment. J Cancer, 2019, 10(4): 829-835.

[10] Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines? Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw, 2023, 21(6): 594-608.

[11] Trancart M, Cavailhes A, Balme B, et al. Anastrozole-induced subacute cutaneous lupus erythematosus. Br J Dermatol, 2008, 158(3): 628-629.

[12] Kurtyka DJ, Mohebbi AD, Burke KT, et al. Subacute cutaneous lupus erythematosus following abemaciclib therapy for metastatic breast cancer. JAAD Case Rep, 2021, 14:10-12.

[13] Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis, 2020, 79(6): 713-723.

[14] Anders HJ, Loutan J, Bruchfeld A, et al. The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. Nephrol Dial Transplant, 2023, 38(3): 551-561.

[15] Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken), 2012, 64(6): 797-808.

[16] Zhou N, Liu Q, Wang X, et al. The combination of hydroxychloroquine and 2-deoxyglucose enhances apoptosis in breast cancer cells by blocking protective autophagy and sustaining endoplasmic reticulum stress. Cell Death Discov, 2022, 8(1): 286.

[17] Olivotto IA, Fairey RN, Gillies JH, et al. Fatal outcome of pelvic radiotherapy for carcinoma of the cervix in a patient with systemic lupus erythematosis. Clin Radiol, 1989, 40(1): 83-84.

[18] Martell K, Long K, Solis A, et al. Systemic Lupus Erythematosus is Not Necessarily a Contraindication to Adjuvant Breast Radiation Therapy. Cureus, 2018, 10(11): e3584.